STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Stopped Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.

Conditions

• Myelodysplastic Syndrome (MDS)

Interventions

• DRUG: MBG453
• DRUG: Azacitidine
• DRUG: Decitabine
• DRUG: INQOVI (oral decitabine)

Sponsor

Novartis Pharmaceuticals